Pneumonia: A Complete Overview

Pneumonia kills over 41,000 Americans annually and hospitalizes 1.3 million — yet it remains significantly preventable through vaccination and timely treatment. Pneumonia is not one disease but a syndrome caused by dozens of different pathogens in a variety of settings, with very different implications for treatment and outcomes.

Key Statistics

• 41,000+ U.S. deaths from pneumonia annually
• 1.3 million hospitalizations per year in the U.S.
• 1.2 million+ emergency department visits annually
• 52% decline in pneumonia mortality since 1999 — thanks to vaccines and improved treatment

What Is Pneumonia?

Pneumonia is an infection of the lung tissue — specifically the alveoli, the tiny air sacs responsible for gas exchange. When bacteria, viruses, fungi, or other pathogens reach the lung tissue, the immune system mounts an inflammatory response. The resulting fluid, pus, and inflammatory cells fill the alveoli, impairing oxygen uptake and producing the characteristic symptoms of fever, cough, and shortness of breath.

In a healthy lung, alveoli are filled with air. In pneumonia, infection triggers the immune system to flood these sacs with fluid and white blood cells — called consolidation. This reduces the lung's ability to transfer oxygen into the bloodstream, causing low oxygen levels (hypoxemia). Consolidation can affect one lobe (lobar pneumonia), multiple patches (bronchopneumonia), or spread bilaterally — which is particularly serious.

Types of Pneumonia

Bacterial Pneumonia Often the most severe form. Common causes: Streptococcus pneumoniae (most common), Haemophilus influenzae, Staphylococcus aureus, Klebsiella. Typical presentation: abrupt fever, productive cough, pleuritic chest pain. Responds to antibiotics — but drug resistance is an increasing concern.

Viral Pneumonia Most common type overall. Causes include influenza, RSV, SARS-CoV-2 (COVID-19), parainfluenza, adenovirus. Generally milder than bacterial pneumonia in healthy adults, but can be severe in elderly and immunocompromised patients. Can pave the way for secondary bacterial pneumonia.

Fungal Pneumonia Primarily affects immunocompromised patients, but Histoplasma capsulatum and Coccidioides (Valley fever) can affect healthy people in endemic regions. Aspergillus primarily affects severely immunosuppressed patients. Requires antifungal therapy, not antibiotics.

Aspiration Pneumonia Caused by inhalation of oral or gastric contents into the lungs. Common in patients with swallowing disorders, reduced consciousness, or neurological disease. Can have very high mortality (up to 70% in severe cases). Typically caused by oral anaerobic bacteria.

"Walking Pneumonia" is a colloquial term for mild pneumonia, most often caused by Mycoplasma pneumoniae or Chlamydophila pneumoniae (atypical organisms). These tend to have a gradual onset, dry cough, and milder symptoms. A major Mycoplasma outbreak surged through U.S. children in 2024.

Community-Acquired vs. Hospital-Acquired

Community-Acquired Pneumonia (CAP): Acquired outside hospital settings. Typical pathogens include S. pneumoniae, Mycoplasma, H. influenzae, and viral causes. Antibiotic resistance is generally lower. Mortality is ~1–5% outpatient; 5–15% hospitalized. First-line treatment: amoxicillin ± macrolide; doxycycline for atypicals.

Hospital-Acquired Pneumonia (HAP/VAP): Develops ≥48 hours after hospital admission. Typical pathogens include MRSA, Pseudomonas, Klebsiella, Acinetobacter — all with high antibiotic resistance. Mortality 15–50%; VAP in ICU patients carries the highest risk. Requires broad-spectrum IV antibiotics with MRSA and Pseudomonas coverage.

Symptoms

• Fever, chills, or rigors
• Productive cough (may be rusty or yellow-green sputum)
• Shortness of breath
• Pleuritic chest pain (sharp, worsens with breathing)
• Fatigue and malaise
• Confusion or altered mental status (especially in elderly)
• Low oxygen saturation
• Nausea, vomiting, or diarrhea (more common with atypical pneumonias)
• Rapid heart rate and breathing rate

Seek emergency care immediately if symptoms include: confusion or disorientation, oxygen saturation below 92%, severe rapid breathing, cyanosis (blue-tinged lips or fingertips), or inability to maintain adequate fluid intake.

Who Is Most at Risk?

• Adults 65 and older — immune response diminishes with age; swallowing reflexes may also weaken
• Infants and young children — immature immune systems; RSV and bacterial pneumonia are leading causes of child mortality globally
• Smokers — cigarette smoke damages the cilia that clear pathogens from airways; doubles pneumonia risk
• People with chronic lung disease (COPD, asthma, bronchiectasis)
• People with diabetes, heart disease, liver disease, or kidney disease
• Immunocompromised patients — HIV, cancer therapy, organ transplant, biologics
• Residents of long-term care facilities

Diagnosis

1. Clinical assessment — history, vital signs, and physical examination (auscultation for crackles, bronchial breathing, or dullness to percussion)
2. Chest X-ray (CXR) — standard first imaging test; shows consolidation in affected lung segments
3. CT chest — more sensitive than CXR; detects pneumonia earlier and identifies complications like pleural effusion, empyema, or abscess
4. Laboratory tests — CBC, CRP, procalcitonin, blood cultures, sputum culture, urinary antigen tests for S. pneumoniae and Legionella
5. CURB-65 severity scoring — guides hospitalization decisions. One point each for: Confusion, Urea >7 mmol/L, Respiratory rate ≥30/min, Blood pressure <90/60, Age ≥65. Score 0–1 = outpatient; 2 = consider admission; 3+ = hospitalize.

Treatment

Mild CAP (outpatient): Amoxicillin or doxycycline. Macrolide added if atypical pathogen suspected. Most patients recover within 1–2 weeks.

Moderate CAP (hospitalized): Beta-lactam + macrolide or respiratory fluoroquinolone. IV to oral step-down when clinically stable.

Severe CAP (ICU): Beta-lactam + macrolide or fluoroquinolone + anti-pseudomonal coverage if risk factors. Add MRSA coverage if indicated. Corticosteroids may reduce mortality in severe CAP.

Hospital-Acquired / VAP: Broad-spectrum IV antibiotics covering MRSA and Pseudomonas (piperacillin-tazobactam, meropenem, or cefepime ± vancomycin).

Viral Pneumonia (influenza): Oseltamivir (Tamiflu) — within 48 hours of symptom onset. Antibiotics added if secondary bacterial pneumonia suspected.

Fungal Pneumonia: Itraconazole (histoplasmosis, coccidioidomycosis) or voriconazole (aspergillosis). Duration typically months.

Note: Patients often feel worse before they feel better — it typically takes 3–5 days after starting antibiotics before significant improvement. Fatigue may persist for several weeks. Full radiographic clearance on CXR may lag 4–8 weeks behind clinical recovery.

Prevention

Pneumococcal Vaccines (PCV15, PCV20, PPSV23): Recommended for all adults 65+ and younger adults with high-risk conditions. PCV20 provides the broadest coverage with a single shot. Only 24.9% of U.S. adults have received pneumococcal vaccination — leaving 3 in 4 adults unprotected.

Annual Influenza Vaccine: Reduces influenza-related pneumonia risk directly and prevents secondary bacterial pneumonia after flu.

RSV Vaccine (Adults 60+): RSV vaccines (Abrysvo, Mresvia) approved for adults 60+. Nirsevimab provides RSV protection for infants.

Smoking Cessation: Smoking doubles pneumonia risk. Quitting restores mucociliary clearance and immune function within months.

Hand Hygiene & Infection Control: Frequent handwashing and respiratory etiquette reduce transmission of respiratory pathogens.

Managing Underlying Conditions: Controlling diabetes, COPD, heart failure, and other chronic conditions reduces vulnerability. Good nutrition and physical activity support immune function.